Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

SYK inhibitor entospletinib prevents ocular and skin GVHD in mice.

Poe JC, Jia W, Di Paolo JA, Reyes NJ, Kim JY, Su H, Sundy JS, Cardones AR, Perez VL, Chen BJ, Chao NJ, Cardona DM, Saban DR, Sarantopoulos S.

JCI Insight. 2018 Oct 4;3(19). pii: 122430. doi: 10.1172/jci.insight.122430.

2.

An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD.

Poe JC, Jia W, Su H, Anand S, Rose JJ, Tata PV, Suthers AN, Jones CD, Kuan PF, Vincent BG, Serody JS, Horwitz ME, Ho VT, Pavletic SZ, Hakim FT, Owzar K, Zhang D, Blazar BR, Siebel CW, Chao NJ, Maillard I, Sarantopoulos S.

Blood. 2017 Nov 9;130(19):2131-2145. doi: 10.1182/blood-2017-05-782466. Epub 2017 Aug 29.

3.

The Regulatory B Cell Compartment Expands Transiently During Childhood and Is Contracted in Children With Autoimmunity.

Kalampokis I, Venturi GM, Poe JC, Dvergsten JA, Sleasman JW, Tedder TF.

Arthritis Rheumatol. 2017 Jan;69(1):225-238. doi: 10.1002/art.39820. Erratum in: Arthritis Rheumatol. 2017 Oct;69(10 ):2080.

4.

Galectin-1 drives lymphoma CD20 immunotherapy resistance: validation of a preclinical system to identify resistance mechanisms.

Lykken JM, Horikawa M, Minard-Colin V, Kamata M, Miyagaki T, Poe JC, Tedder TF.

Blood. 2016 Apr 14;127(15):1886-95. doi: 10.1182/blood-2015-11-681130. Epub 2016 Feb 17.

5.

Rad18 confers hematopoietic progenitor cell DNA damage tolerance independently of the Fanconi Anemia pathway in vivo.

Yang Y, Poe JC, Yang L, Fedoriw A, Desai S, Magnuson T, Li Z, Fedoriw Y, Araki K, Gao Y, Tateishi S, Sarantopoulos S, Vaziri C.

Nucleic Acids Res. 2016 May 19;44(9):4174-88. doi: 10.1093/nar/gkw072. Epub 2016 Feb 15.

6.

Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease.

Flynn R, Allen JL, Luznik L, MacDonald KP, Paz K, Alexander KA, Vulic A, Du J, Panoskaltsis-Mortari A, Taylor PA, Poe JC, Serody JS, Murphy WJ, Hill GR, Maillard I, Koreth J, Cutler CS, Soiffer RJ, Antin JH, Ritz J, Chao NJ, Clynes RA, Sarantopoulos S, Blazar BR.

Blood. 2015 Jun 25;125(26):4085-94. doi: 10.1182/blood-2014-08-595470. Epub 2015 Apr 7.

7.

A spontaneous deletion within the desmoglein 3 extracellular domain of mice results in hypomorphic protein expression, immunodeficiency, and a wasting disease phenotype.

Kountikov EI, Poe JC, Maclver NJ, Rathmell JC, Tedder TF.

Am J Pathol. 2015 Mar;185(3):617-30. doi: 10.1016/j.ajpath.2014.10.025. Epub 2014 Dec 24.

8.

A reevaluation of CD22 expression in human lung cancer.

Pop LM, Barman S, Shao C, Poe JC, Venturi GM, Shelton JM, Pop IV, Gerber DE, Girard L, Liu XY, Behrens C, Rodriguez-Canales J, Liu H, Wistuba II, Richardson JA, Minna JD, Tedder TF, Vitetta ES.

Cancer Res. 2014 Jan 1;74(1):263-71. doi: 10.1158/0008-5472.CAN-13-1436.

9.

EndoU is a novel regulator of AICD during peripheral B cell selection.

Poe JC, Kountikov EI, Lykken JM, Natarajan A, Marchuk DA, Tedder TF.

J Exp Med. 2014 Jan 13;211(1):57-69. doi: 10.1084/jem.20130648. Epub 2013 Dec 16.

10.

Peritoneal cavity regulatory B cells (B10 cells) modulate IFN-γ+CD4+ T cell numbers during colitis development in mice.

Maseda D, Candando KM, Smith SH, Kalampokis I, Weaver CT, Plevy SE, Poe JC, Tedder TF.

J Immunol. 2013 Sep 1;191(5):2780-2795. doi: 10.4049/jimmunol.1300649. Epub 2013 Aug 5.

11.

Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions.

Yoshizaki A, Miyagaki T, DiLillo DJ, Matsushita T, Horikawa M, Kountikov EI, Spolski R, Poe JC, Leonard WJ, Tedder TF.

Nature. 2012 Nov 8;491(7423):264-8. doi: 10.1038/nature11501. Epub 2012 Oct 14.

12.

A c-Myc and surface CD19 signaling amplification loop promotes B cell lymphoma development and progression in mice.

Poe JC, Minard-Colin V, Kountikov EI, Haas KM, Tedder TF.

J Immunol. 2012 Sep 1;189(5):2318-25. doi: 10.4049/jimmunol.1201000. Epub 2012 Jul 23.

13.

CD22 and Siglec-G in B cell function and tolerance.

Poe JC, Tedder TF.

Trends Immunol. 2012 Aug;33(8):413-20. doi: 10.1016/j.it.2012.04.010. Epub 2012 Jun 5. Review.

14.

Susac syndrome: an organ-specific autoimmune endotheliopathy syndrome associated with anti-endothelial cell antibodies.

Magro CM, Poe JC, Lubow M, Susac JO.

Am J Clin Pathol. 2011 Dec;136(6):903-12. doi: 10.1309/AJCPERI7LC4VNFYK.

PMID:
22095376
15.

Amplified B lymphocyte CD40 signaling drives regulatory B10 cell expansion in mice.

Poe JC, Smith SH, Haas KM, Yanaba K, Tsubata T, Matsushita T, Tedder TF.

PLoS One. 2011;6(7):e22464. doi: 10.1371/journal.pone.0022464. Epub 2011 Jul 25.

16.

Degos disease: a C5b-9/interferon-α-mediated endotheliopathy syndrome.

Magro CM, Poe JC, Kim C, Shapiro L, Nuovo G, Crow MK, Crow YJ.

Am J Clin Pathol. 2011 Apr;135(4):599-610. doi: 10.1309/AJCP66QIMFARLZKI.

PMID:
21411783
17.

B-cell homeostasis requires complementary CD22 and BLyS/BR3 survival signals.

Smith SH, Haas KM, Poe JC, Yanaba K, Ward CD, Migone TS, Tedder TF.

Int Immunol. 2010 Aug;22(8):681-91. doi: 10.1093/intimm/dxq055. Epub 2010 May 31.

18.

CD21/35 promotes protective immunity to Streptococcus pneumoniae through a complement-independent but CD19-dependent pathway that regulates PD-1 expression.

Haas KM, Poe JC, Tedder TF.

J Immunol. 2009 Sep 15;183(6):3661-71. doi: 10.4049/jimmunol.0901218. Epub 2009 Aug 26.

19.

Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV.

Minard-Colin V, Xiu Y, Poe JC, Horikawa M, Magro CM, Hamaguchi Y, Haas KM, Tedder TF.

Blood. 2008 Aug 15;112(4):1205-13. doi: 10.1182/blood-2008-01-135160. Epub 2008 May 21.

20.

A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses.

Yanaba K, Bouaziz JD, Haas KM, Poe JC, Fujimoto M, Tedder TF.

Immunity. 2008 May;28(5):639-50. doi: 10.1016/j.immuni.2008.03.017.

21.

CD22 regulates time course of both B cell division and antibody response.

Onodera T, Poe JC, Tedder TF, Tsubata T.

J Immunol. 2008 Jan 15;180(2):907-13.

22.

Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice.

Bouaziz JD, Yanaba K, Venturi GM, Wang Y, Tisch RM, Poe JC, Tedder TF.

Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20878-83. Epub 2007 Dec 19.

23.

CD22 ligand binding regulates normal and malignant B lymphocyte survival in vivo.

Haas KM, Sen S, Sanford IG, Miller AS, Poe JC, Tedder TF.

J Immunol. 2006 Sep 1;177(5):3063-73.

24.

B cell antigen receptor and CD40 differentially regulate CD22 tyrosine phosphorylation.

Fujimoto M, Kuwano Y, Watanabe R, Asashima N, Nakashima H, Yoshitake S, Okochi H, Tamaki K, Poe JC, Tedder TF, Sato S.

J Immunol. 2006 Jan 15;176(2):873-9.

25.
26.

CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction.

Tedder TF, Poe JC, Haas KM.

Adv Immunol. 2005;88:1-50. Review.

PMID:
16227086
27.

Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease.

Yazawa N, Hamaguchi Y, Poe JC, Tedder TF.

Proc Natl Acad Sci U S A. 2005 Oct 18;102(42):15178-83. Epub 2005 Oct 10.

29.

The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice.

Hamaguchi Y, Uchida J, Cain DW, Venturi GM, Poe JC, Haas KM, Tedder TF.

J Immunol. 2005 Apr 1;174(7):4389-99.

30.
31.

CD22 regulates B lymphocyte function in vivo through both ligand-dependent and ligand-independent mechanisms.

Poe JC, Fujimoto Y, Hasegawa M, Haas KM, Miller AS, Sanford IG, Bock CB, Fujimoto M, Tedder TF.

Nat Immunol. 2004 Oct;5(10):1078-87. Epub 2004 Sep 19.

PMID:
15378059
32.

The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy.

Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM, Tedder TF.

J Exp Med. 2004 Jun 21;199(12):1659-69.

33.

Cutting edge: C3d functions as a molecular adjuvant in the absence of CD21/35 expression.

Haas KM, Toapanta FR, Oliver JA, Poe JC, Weis JH, Karp DR, Bower JF, Ross TM, Tedder TF.

J Immunol. 2004 May 15;172(10):5833-7.

35.

Mouse CD20 expression and function.

Uchida J, Lee Y, Hasegawa M, Liang Y, Bradney A, Oliver JA, Bowen K, Steeber DA, Haas KM, Poe JC, Tedder TF.

Int Immunol. 2004 Jan;16(1):119-29.

PMID:
14688067
36.

The tetraspanin CD81 regulates the expression of CD19 during B cell development in a postendoplasmic reticulum compartment.

Shoham T, Rajapaksa R, Boucheix C, Rubinstein E, Poe JC, Tedder TF, Levy S.

J Immunol. 2003 Oct 15;171(8):4062-72.

37.

Complement receptors CD21/35 link innate and protective immunity during Streptococcus pneumoniae infection by regulating IgG3 antibody responses.

Haas KM, Hasegawa M, Steeber DA, Poe JC, Zabel MD, Bock CB, Karp DR, Briles DE, Weis JH, Tedder TF.

Immunity. 2002 Dec;17(6):713-23.

38.
39.

A functional role for circulating mouse L-selectin in regulating leukocyte/endothelial cell interactions in vivo.

Tu L, Poe JC, Kadono T, Venturi GM, Bullard DC, Tedder TF, Steeber DA.

J Immunol. 2002 Aug 15;169(4):2034-43.

40.

Complementary roles for CD19 and Bruton's tyrosine kinase in B lymphocyte signal transduction.

Fujimoto M, Poe JC, Satterthwaite AB, Wahl MI, Witte ON, Tedder TF.

J Immunol. 2002 Jun 1;168(11):5465-76.

41.

CD19, CD21, and CD22: multifaceted response regulators of B lymphocyte signal transduction.

Poe JC, Hasegawa M, Tedder TF.

Int Rev Immunol. 2001;20(6):739-62. Review.

PMID:
11913948
42.

CD19 amplification of B lymphocyte Ca2+ responses: a role for Lyn sequestration in extinguishing negative regulation.

Fujimoto M, Poe JC, Hasegawa M, Tedder TF.

J Biol Chem. 2001 Nov 30;276(48):44820-7. Epub 2001 Oct 2.

43.

CD19 can regulate B lymphocyte signal transduction independent of complement activation.

Hasegawa M, Fujimoto M, Poe JC, Steeber DA, Tedder TF.

J Immunol. 2001 Sep 15;167(6):3190-200.

44.

A CD19-dependent signaling pathway regulates autoimmunity in Lyn-deficient mice.

Hasegawa M, Fujimoto M, Poe JC, Steeber DA, Lowell CA, Tedder TF.

J Immunol. 2001 Sep 1;167(5):2469-78.

45.

CD19 regulates intrinsic B lymphocyte signal transduction and activation through a novel mechanism of processive amplification.

Fujimoto M, Poe JC, Hasegawa M, Tedder TF.

Immunol Res. 2000;22(2-3):281-98. Review.

PMID:
11339363
46.

CD19 regulates Src family protein tyrosine kinase activation in B lymphocytes through processive amplification.

Fujimoto M, Fujimoto Y, Poe JC, Jansen PJ, Lowell CA, DeFranco AL, Tedder TF.

Immunity. 2000 Jul;13(1):47-57.

47.

CD19 and CD22 regulate a B lymphocyte signal transduction pathway that contributes to autoimmunity.

Tedder TF, Sato S, Poe JC, Fujimoto M.

Keio J Med. 2000 Mar;49(1):1-13.

48.
49.

Modulation of B lymphocyte antigen receptor signal transduction by a CD19/CD22 regulatory loop.

Fujimoto M, Bradney AP, Poe JC, Steeber DA, Tedder TF.

Immunity. 1999 Aug;11(2):191-200.

50.

CD19 amplifies B lymphocyte signal transduction by regulating Src-family protein tyrosine kinase activation.

Fujimoto M, Poe JC, Jansen PJ, Sato S, Tedder TF.

J Immunol. 1999 Jun 15;162(12):7088-94.

Supplemental Content

Support Center